Enlarge / Robert J. Coury of Mylan (L) and Mylan CEO Heather Bresch attend a benefit in New York City on November 2, 2015. (credit: Getty | Gilbert Carrasquillo)
Last year, furor over the skyrocketing price of Mylan’s life-saving EpiPens hit a fever pitch. Lawmakers seethed, parents broke into tears at pharmacy counters, regulators opened investigations, competitors raced to come up with cheaper alternatives, and Mylan’s stock tumbled 29 percent.
Nevertheless, Mylan chairman, Robert Coury received compensation of $ 97.6 million in 2016. And that doesn’t include an additional $ 66.3 million in other retirement benefits and payments that Coury received last year as part of a transition from executive chairman to a “non-employee chairman role.” Coury will continue to receive a $ 1.8 million per year “cash retainer” as part of a deal made with Mylan last year.
The payments were disclosed Monday in a US Securities and Exchange Commission filing.
Read 7 remaining paragraphs | Comments
